Heterocyclic nuclear hormone receptor modulators

US9150592B2 · kind B2 · utility

Assignee

• Abb Vie Inc. · US

Inventors

• Kevin P. Cusack · Holden, US
• Thomas D. Gordon · Medway, US
• Michael Z. Hoemann · Marlborough, US
• David C. Ihle · Worcester, US
• Bin Li · Columbus, US
• Gloria Y. Lo Schiavo · Shrewsbury, US
• Gagandeep Somal · Ashland, US
• Michael Friedman · Jerusalem, IL
• Martin E. Hayes · Lowell, US
• Wouter Bakker · Weesp, NL

Key dates

• Filing date: Dec 20, 2013
• Grant date: Oct 6, 2015
• Expiry date: Dec 20, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D513/20
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The invention provides a compound of Formula (I)pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.